Harvard Bioscience (HBIO) vs Precipio (PRPO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Precipio (PRPO) over the past year, gaining 87.3% versus a gain of 17.6%. Over five years, PRPO leads with a -54.8% price change compared with -88.1% for HBIO. Precipio is the larger company by market cap ($41.4 million vs $37.5 million), about 1.1 times the size.
On valuation, Harvard Bioscience trades at a lower forward P/E (12.8x vs 59.3x for Precipio).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HBIO | PRPO |
|---|---|---|
| Share price | $8.24 | $23.12 |
| Market cap | $37.51M | $41.39M |
| 1-day change | +1.35% | -0.30% |
| YTD return | +22.99% | +0.61% |
| 1-year return | +87.27% | +17.60% |
| 5-year return | -88.11% | -54.84% |
| Forward P/E | 12.78 | 59.28 |
| EPS (TTM) | $-2.31 | $-0.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.40 | $33.63 |
| 52-week low | $3.80 | $16.40 |
| Distance from 52-week high | -12.34% | -31.25% |
| Analyst consensus | none | — |
| Avg. price target upside | -8.98% | — |
| Average volume | 18.14K | 127.60K |
| Shares outstanding | 4.55M | 1.79M |
| Employees | 316 | 61 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HBIO has outperformed PRPO by 69.7 percentage points over the past year.
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
About Precipio
PRPO stock →Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 61 employees
HBIO vs PRPO FAQ
Which is bigger, Harvard Bioscience or Precipio?
Precipio (PRPO) is larger, with a market capitalization of $41.39M compared with $37.51M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, HBIO or PRPO?
HBIO returned +87.27% over the past 12 months, compared with +17.60% for PRPO (price return, excluding dividends). Past performance does not predict future results.
Are Harvard Bioscience and Precipio in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.